Literature DB >> 29110408

Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.

Arun K Ghosh1, W Sean Fyvie1, Margherita Brindisi1, Melinda Steffey1, Johnson Agniswamy2, Yuan-Fang Wang2, Manabu Aoki3, Masayuki Amano3, Irene T Weber2, Hiroaki Mitsuya3,4,5.   

Abstract

The structure-based design, synthesis, and biological evaluation of a series of nonpeptidic HIV-1 protease inhibitors with rationally designed P2' ligands are described. The inhibitors are designed to enhance backbone binding interactions, particularly at the S2' subsite. Synthesis of inhibitors was carried out efficiently. The stereochemistry of alcohol functionalities of the P2' ligands was set by asymmetric reduction of the corresponding ketone using (R,R)- or (S,S)-Noyori catalysts. A number of inhibitors displayed very potent enzyme inhibitory and antiviral activity. Inhibitors 3g and 3h showed enzyme Ki values of 27.9 and 49.7 pm and antiviral activity of 6.2 and 3.9 nm, respectively. These inhibitors also remained quite potent against darunavir-resistant HIV-1 variants. An X-ray structure of inhibitor 3g in complex with HIV-1 protease revealed key interactions in the S2' subsite.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  HIV-1 protease inhibitors; P2′ ligands; drug resistance; pharmacokinetics; structure-based design

Mesh:

Substances:

Year:  2017        PMID: 29110408      PMCID: PMC5896574          DOI: 10.1002/cmdc.201700614

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  41 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

3.  A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.

Authors:  Ravikiran S Yedidi; Harisha Garimella; Manabu Aoki; Hiromi Aoki-Ogata; Darshan V Desai; Simon B Chang; David A Davis; W Sean Fyvie; Joshua D Kaufman; David W Smith; Debananda Das; Paul T Wingfield; Kenji Maeda; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

Review 4.  Current status and prospects of HIV treatment.

Authors:  Tomas Cihlar; Marshall Fordyce
Journal:  Curr Opin Virol       Date:  2016-03-28       Impact factor: 7.090

5.  In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.

Authors:  Yasuhiro Koh; Masayuki Amano; Tomomi Towata; Matthew Danish; Sofiya Leshchenko-Yashchuk; Debananda Das; Maki Nakayama; Yasushi Tojo; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

Review 6.  HIV infection: epidemiology, pathogenesis, treatment, and prevention.

Authors:  Gary Maartens; Connie Celum; Sharon R Lewin
Journal:  Lancet       Date:  2014-06-05       Impact factor: 79.321

7.  GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.

Authors:  Yasuhiro Koh; Debananda Das; Sofiya Leschenko; Hirotomo Nakata; Hiromi Ogata-Aoki; Masayuki Amano; Maki Nakayama; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.

Authors:  Ravindra Gupta; Andrew Hill; Anthony W Sawyer; Deenan Pillay
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

9.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  3 in total

1.  Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.

Authors:  Gordon J Lockbaum; Florian Leidner; Linah N Rusere; Mina Henes; Klajdi Kosovrasti; Gily S Nachum; Ellen A Nalivaika; Akbar Ali; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  ACS Infect Dis       Date:  2018-12-31       Impact factor: 5.084

2.  Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.

Authors:  Arun K Ghosh; Zilei Xia; Satish Kovela; William L Robinson; Megan E Johnson; Daniel W Kneller; Yuan-Fang Wang; Manabu Aoki; Yuki Takamatsu; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2019-10-04       Impact factor: 3.466

3.  HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.

Authors:  Linah N Rusere; Gordon J Lockbaum; Sook-Kyung Lee; Mina Henes; Klajdi Kosovrasti; Ean Spielvogel; Ellen A Nalivaika; Ronald Swanstrom; Nese Kurt Yilmaz; Celia A Schiffer; Akbar Ali
Journal:  J Med Chem       Date:  2019-08-21       Impact factor: 7.446

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.